Myara I, Myara A, Mangeot M, Fabre M, Charpentier C, Lemonnier A
Clin Chem. 1984 Feb;30(2):211-5.
We describe here an easy method of determining prolidase (EC 3.4.13.9) in plasma after preincubation with Mn2+ for 24 h at 37 degrees C to maximize prolidase activity. The mean activity in 338 patients who were either in hospital or outpatients was 900 U/L +/- 520 (2 SD), unrelated to sex or age. In 25 of these 338 samples tested, prolidase activity was between 1500 and 2000 U/L. It exceeded 2000 U/L in eight, all of whom were patients with chronic liver disease. Plasma prolidase activity was normal in cytolytic syndromes such as liver or heart disease. Of the 27 patients with cirrhosis, only five exhibited prolidase activity greater than 2000 U/L. Plasma prolidase activity was uncorrelated with six biochemical indexes to liver function (the aminotransferases, alkaline phosphatase, glutamyltransferase, total bilirubin, and serum albumin) or with the degree of cirrhotic fibrosis. We believe that plasma prolidase activity may be high only in the early stage of fibrosis. This hypothesis would be consistent with the data on rat-liver collagenolytic activities during CCl4 administration. Monitoring of plasma prolidase activity might be useful in evaluating fibrotic processes in chronic liver disease in the human.
我们在此描述一种简便的方法，用于测定血浆中的脯氨酰二肽酶（EC 3.4.13.9）。将血浆与Mn2+在37℃预孵育24小时，以使脯氨酰二肽酶活性最大化。338例住院患者或门诊患者的平均活性为900 U/L±520（2个标准差），与性别或年龄无关。在这338份检测样本中，有25份的脯氨酰二肽酶活性在1500至2000 U/L之间。有8份样本的活性超过2000 U/L，这些样本的患者均为慢性肝病患者。在诸如肝病或心脏病等细胞溶解性综合征中，血浆脯氨酰二肽酶活性正常。27例肝硬化患者中，只有5例的脯氨酰二肽酶活性大于2000 U/L。血浆脯氨酰二肽酶活性与六项肝功能生化指标（转氨酶、碱性磷酸酶、谷氨酰转移酶、总胆红素和血清白蛋白）或肝硬化纤维化程度无关。我们认为，血浆脯氨酰二肽酶活性可能仅在纤维化早期较高。这一假设与四氯化碳给药期间大鼠肝脏胶原酶活性的数据相符。监测血浆脯氨酰二肽酶活性可能有助于评估人类慢性肝病中的纤维化进程。
